The Latest Breaking News from Pfizer

The S&P 500 is coming off its four-week win streak amid signals of cooling price increases. However, inflation is still running hot near a 40-year high, which might induce the Fed to continue its policy rate hikes. We think income stocks AbbVie (ABBV), Amgen (AMGN), Pfizer (PFE), Bristol-Myers Squibb (BMY),…

JCVI says mRNA vaccines such as the Pfizer and Moderna jabs are the most effective for UK booster programme

It's not known how long the vaccines will offer protection for, experts have admitted

In the U.S., officials have asked vaccine makers to target BA.5, rather than the original omicron strain. That has delayed the boosters' development — but officials hope they will be more effective.

The comments come after it emerged that current stock would cover only half the population eligible for the booster jab.

Some people will be offered a Moderna jab and others the Pfizer vaccine

Albert Bourla has already received four doses of the Pfizer-BioNTech vaccine

The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms

The autumn booster program for Covid vaccinations will begin shortly. Over 50s, carers, frontline health workers and those at clinical risk will be inited to get a booster jab.

The groundbreaking Moderna jabs, which target both the Omicron variant and the original strain of the killer virus, will be rolled out in a bid to avoid a winter NHS nightmare

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…